用于膀胱癌检测和监测的尿液细胞学及辅助标志物。
Urine cytology and adjunct markers for detection and surveillance of bladder cancer.
作者信息
Sullivan Peggy S, Chan Jessica B, Levin Mary R, Rao Jianyu
出版信息
Am J Transl Res. 2010 Jul 25;2(4):412-40.
Abstract
Urine cytology coupled with cystoscopic examination has been and remains the standard in the initial evaluation of lower urinary tract lesions to rule out bladder cancer. However, cystoscopy is invasive and may miss some flat lesions, whereas cytology has low sensitivity in low-grade papillary disease. Additional lab-based or office-based markers are needed to aid in the evaluation of these lesions. Recently, many such markers have been developed for the purpose of improving the cytologic diagnosis of bladder malignancies. In this review, we will first discuss conventional cytomorphologic analysis of urine cytology followed by a discussion of markers that have been developed in the past for detection and surveillance of urothelial carcinoma. We will focus on how these markers can be used in conjunction with urine cytology in daily practice.
摘要
尿细胞学检查结合膀胱镜检查一直是并仍然是初步评估下尿路病变以排除膀胱癌的标准方法。然而，膀胱镜检查具有侵入性，可能会遗漏一些扁平病变，而细胞学检查在低级别乳头状疾病中的敏感性较低。需要额外的基于实验室或门诊的标志物来辅助评估这些病变。最近，为了改善膀胱恶性肿瘤的细胞学诊断，已经开发了许多这样的标志物。在这篇综述中，我们将首先讨论尿细胞学的传统细胞形态学分析，然后讨论过去开发的用于检测和监测尿路上皮癌的标志物。我们将重点讨论这些标志物如何在日常实践中与尿细胞学检查结合使用。
相似文献
1
Urine cytology and adjunct markers for detection and surveillance of bladder cancer.用于膀胱癌检测和监测的尿液细胞学及辅助标志物。
Am J Transl Res. 2010 Jul 25;2(4):412-40.
2
Urine-Based Markers for Detection of Urothelial Cancer and for the Management of Non-muscle-Invasive Bladder Cancer.基于尿液的标志物用于检测尿路上皮癌和管理非肌肉浸润性膀胱癌。
Urol Clin North Am. 2023 Feb;50(1):53-67. doi: 10.1016/j.ucl.2022.09.009.
3
Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.NMP22膀胱检测试验与尿液细胞学检查在复发性膀胱癌检测中的比较。
Jpn J Clin Oncol. 2006 Mar;36(3):172-5. doi: 10.1093/jjco/hyi244. Epub 2006 Mar 6.
4
Cytologic and cystoscopic predictors of recurrence and progression in patients with low-grade urothelial carcinoma.细胞学和膀胱镜预测低级别尿路上皮癌患者的复发和进展。
Cancer Cytopathol. 2013 Jul;121(7):398-402. doi: 10.1002/cncy.21272. Epub 2013 Jan 30.
5
Evaluation of the Value of Combined Urine Cytology and Cystoscopy for Follow-up of Superficial Transitional Cell Carcinoma of the Urinary Bladder.联合尿细胞学检查和膀胱镜检查对膀胱浅表性移行细胞癌随访的价值评估
J Egypt Natl Canc Inst. 2010 Jun;22(2):105-11.
6
Tumor markers for the early detection of bladder cancer.用于早期检测膀胱癌的肿瘤标志物。
Front Biosci. 2002 Jan 1;7:e19-26. doi: 10.2741/A901.
7
Urine markers for detection and surveillance of bladder cancer.用于膀胱癌检测和监测的尿液标志物。
Urol Oncol. 2014 Apr;32(3):222-9. doi: 10.1016/j.urolonc.2013.06.001. Epub 2013 Sep 17.
8
NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study.核基质蛋白-22、尿液细胞学检查和膀胱镜检查：一项为期1年的比较研究。
Can J Urol. 2012 Aug;19(4):6345-50.
9
The effects of the current World Health Organization/International Society of Urologic Pathologists bladder neoplasm classification system on urine cytology results.当前世界卫生组织/国际泌尿病理学家学会膀胱肿瘤分类系统对尿液细胞学检查结果的影响。
Cancer. 2002 Jun 25;96(3):140-5. doi: 10.1002/cncr.10621.
10
Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.非肌层浸润性膀胱癌的随访——国际膀胱癌网络建议
Urol Oncol. 2016 Oct;34(10):460-8. doi: 10.1016/j.urolonc.2016.05.028. Epub 2016 Jun 29.
引用本文的文献
1
Unleashing the power of urine‑based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review).释放基于尿液的生物标志物在膀胱癌诊断、预后和监测中的力量（综述）。
Int J Oncol. 2025 Mar;66(3). doi: 10.3892/ijo.2025.5724. Epub 2025 Feb 7.
2
Urinary DNA Methylation Test for Bladder Cancer Diagnosis.用于膀胱癌诊断的尿液DNA甲基化检测
JAMA Oncol. 2025 Mar 1;11(3):293-299. doi: 10.1001/jamaoncol.2024.6160.
3
Is prostatic adenocarcinoma detectable by urine cytology-A multicenter retrospective review.尿细胞学检查能否检测出前列腺腺癌——一项多中心回顾性研究
Prostate. 2025 Jan;85(1):97-104. doi: 10.1002/pros.24805. Epub 2024 Oct 14.
4
The Simultaneous Use of Bladder Epicheck and Urinary Cytology Can Improve the Sensitivity and Specificity of Diagnostic Follow-Up of Urothelial Lesions: Up-to-Date Data from a Multi-Institutional Cohort.膀胱上皮检查与尿细胞学联合应用可提高尿路上皮病变诊断随访的敏感性和特异性：来自多机构队列的最新数据
Diseases. 2024 Sep 18;12(9):219. doi: 10.3390/diseases12090219.
5
Urinary mRNA-based biomarkers for non-muscle-invasive bladder cancer: a mini-review.基于尿液mRNA的非肌层浸润性膀胱癌生物标志物：一篇综述
Front Oncol. 2024 Aug 9;14:1441883. doi: 10.3389/fonc.2024.1441883. eCollection 2024.
6
Cancer cell mechanobiology: a new frontier for cancer research.癌细胞力学生物学：癌症研究的新前沿。
J Natl Cancer Cent. 2021 Dec 4;2(1):10-17. doi: 10.1016/j.jncc.2021.11.007. eCollection 2022 Mar.
7
Bladder Cancer and Artificial Intelligence: Emerging Applications.膀胱癌与人工智能：新兴应用
Urol Clin North Am. 2024 Feb;51(1):63-75. doi: 10.1016/j.ucl.2023.07.002. Epub 2023 Aug 25.
8
Diagnostic Significance of Cytokeratin 20 and p53 as Adjunct Immunocytological Markers in Urine Cytology to Detect Urothelial Carcinomas: A Systematic Review Study.细胞角蛋白20和p53作为尿液细胞学辅助免疫细胞标志物在检测尿路上皮癌中的诊断意义：一项系统评价研究
Iran J Pathol. 2023 Summer;18(3):257-269. doi: 10.30699/IJP.2023.1972203.3004. Epub 2023 Jul 16.
9
MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma.MCM4 表达与尿路上皮癌的高级别组织学、肿瘤进展和不良预后相关。
Diagn Pathol. 2023 Sep 22;18(1):106. doi: 10.1186/s13000-023-01392-y.
10
Examining longitudinal markers of bladder cancer recurrence through a semiautonomous machine learning system for quantifying specimen atypia from urine cytology.通过半自主机器学习系统定量分析尿液细胞学标本非典型性，检测膀胱癌复发的纵向标志物。
Cancer Cytopathol. 2023 Sep;131(9):561-573. doi: 10.1002/cncy.22725. Epub 2023 Jun 26.
本文引用的文献
1
Clinical experience with survivin as a biomarker for urothelial bladder cancer.生存素作为膀胱癌生物标志物的临床经验。
World J Urol. 2010 Jun;28(3):399-404. doi: 10.1007/s00345-010-0538-2. Epub 2010 Mar 23.
2
Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients.尿端粒酶活性检测在有症状患者膀胱癌中的准确性。
Int J Biol Markers. 2009 Oct-Dec;24(4):253-7. doi: 10.1177/172460080902400406.
3
Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer.Hyal1 和 survivin RNA 的表达可作为膀胱癌的诊断分子标志物。
J Urol. 2010 Feb;183(2):493-8. doi: 10.1016/j.juro.2009.10.024. Epub 2009 Dec 14.
4
Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.通过实时甲基化特异性聚合酶链反应检测尿液样本中 TWIST1 和 NID2 基因的甲基化，用于原发性膀胱癌的非侵入性检测。
Eur Urol. 2010 Jul;58(1):96-104. doi: 10.1016/j.eururo.2009.07.041. Epub 2009 Aug 5.
5
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer.前列腺干细胞抗原基因（PSCA）的遗传变异会增加患膀胱癌的易感性。
Nat Genet. 2009 Sep;41(9):991-5. doi: 10.1038/ng.421. Epub 2009 Aug 2.
6
Which urine marker test provides more diagnostic value in conjunction with standard cytology- ImmunoCyt/uCyt+ or Cytokeratin 20 expression.与标准细胞学检查联合使用时，哪种尿液标志物检测提供更多的诊断价值——ImmunoCyt/uCyt+ 还是细胞角蛋白 20 表达。
Diagn Pathol. 2009 Jun 26;4:20. doi: 10.1186/1746-1596-4-20.
7
Cancer statistics, 2009.2009年癌症统计数据。
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.
8
Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.通过细胞学检查和标准化微卫星分析相结合，可提高对排尿中尿路上皮膀胱癌细胞的检测能力。
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1798-806. doi: 10.1158/1055-9965.EPI-09-0099. Epub 2009 May 19.
9
Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study.免疫细胞化学、UroVysion检测法与尿细胞学检查在复发性尿路上皮癌检测中的比较：一项“样本拆分”研究
Cancer. 2009 Jun 25;117(3):167-73. doi: 10.1002/cncy.20026.
Zotero 插件